Takeda Oncology
Frances Fu, PharmD, BCOP, BCSCP, BCMAS, currently serves as a Senior Medical Science Liaison for Solid Tumor Oncology at Takeda Oncology, having joined in May 2023 following a role as Medical Science Liaison focused on solid tumors. Prior to Takeda, Frances held the position of Medical Science Liaison at UroGen Pharma and worked as a Clinical Oncology Pharmacist at Cleveland Clinic. Frances started the professional journey as a PGY1 Pharmacy Resident at Summa Health and gained pharmacy intern experience at multiple institutions, including University Hospitals of Cleveland and Giant Eagle, Inc. Additionally, Frances participated in research as a Summer Research Fellow at Northeast Ohio Medical University, focusing on coronary microvascular mechanisms. Frances earned a PharmD from Northeast Ohio Medical University and a Bachelor of Science in Pharmaceutical Science from The University of Toledo.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.